All data are based on the daily closing price as of March 19, 2025
m

Mycenax Biotech

4726.TWO
1.36 USD
-0.02
-1.45%

Overview

Last close
1.36 usd
Market cap
280.67M usd
52 week high
1.91 usd
52 week low
1.06 usd
Target price
N/A usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
13.6985
Price/Book Value
4.48
Enterprise Value
301.99M usd
EV/Revenue
14.7215
EV/EBITDA
-95.509

Key financials

Revenue TTM
17.59M usd
Gross Profit TTM
-3.51M usd
EBITDA TTM
-7.43M usd
Earnings per Share
-0.08 usd
Dividend
N/A usd
Total assets
109.49M usd
Net debt
12.84M usd

About

Mycenax Biotech Inc., a contract development and manufacturing organization company, provides biopharmaceutical services and solutions for drug development and production in Taiwan, Japan, Korea, Singapore, rest of the Asia-Pacific regions, Europe, and the United States. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug conjugates, cell and gene therapy, and exosomes products and services. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.
  • Symbol
    4726.TWO
  • Exchange
    TWO
  • Isin
    TW0004726005
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
  • Headquarter
    Zhubei
  • Web site
    https://www.mycenax.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top